Background Clinical practice guidelines recommend the use of antenatal magnesium
sulphate for fetal neuroprotection before preterm birth at< 30 weeks' gestation. Aims This …

Health professionals at 25 A ustralian and N ew Z ealand tertiary maternity hospitals were
surveyed about local implementation of a clinical practice guideline for antenatal …

Background Australian and New Zealand clinical practice guidelines, endorsed by the
NHMRC in 2010, recommend administration of antenatal magnesium sulphate to women at …

Objective The objective is to provide guidelines for the use of antenatal magnesium sulphate
for fetal neuroprotection of the preterm infant. Options Antenatal magnesium sulphate …

Background It is important to establish whether research recommendations regarding
magnesium sulphate for neuroprotection can be readily translated into clinical practice and …

Antenatal magnesium sulphate reduces the risk of cerebral palsy in babies born< 30 weeks'
gestation. A guideline for its use in women at imminent risk of preterm birth was …

Background Magnesium sulphate was introduced for fetal neuroprotection in Australia in
2010. The aim of this study was to determine how often antenatal magnesium sulphate is …

Background Strong evidence supports administration of magnesium sulphate prior to birth at
less than 30 weeks' gestation to prevent very preterm babies dying or developing cerebral …

Objective To evaluate a slower (compared with a standard) infusion rate of the loading dose
of magnesium sulphate for preterm fetal neuroprotection as a strategy to reduce maternal …

Background Magnesium sulfate is an accepted intervention for fetal neuroprotection. There
are some perceived differences in the international recommendations on the use …